RE: News14 Apr 2026 18:52
Mallettp
We have known this for a year
“ The agent, oral GaM, is taken daily and has demonstrated excellent tolerability, with no serious adverse events reported.
Among the 23 subjects with evaluable data, early signs of efficacy have been observed, with an overall survival (“OS”) of 32 months. ”
What we are waiting for is the actual results confirming this. I would say they haven’t let any news slip out we didn’t already know, well not to shareholders anyway.
Thanks